To date, PSMA-targeted imaging and therapy have significantly changed the landscape of prostate cancer patient management, further propelling the development of theranostic radiopharmaceuticals, not only for prostate cancer but also for other cancer types or diseases. The gene discussed is FOLH1; the disease is Familial prostate cancer.